Market news
Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methodsDosing of additional patients with the new process at LyFE continues with the goal of determining the recommended Phase 2 dose and optimized safety management plan to support End-of-Phase 1 discussions with the FDAAdditional clinical data from the Phase 1/2 trial of LYL273 in patients with third- or later-line relapsed/refractory metastatic colorectal c
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.
PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in the second half of 2027Presented updated ronde-cel data in more than 100 patients with relapsed/refractory LBCL at the EHA 2026 Congress, with Phase 1/2 safety data showing no Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS supporting potential outpatient administrationReported updated
Lyell Immunopharma (LYEL) has an average rating of overweight and mean price target of $37.88, accor
This is the newest page. Registered accounts read further back.